DW51212

DW51212 is an investigational drug evaluated as a comparator in a Phase 3, randomized, double-blind, multi-center clinical trial for the treatment of acute bronchitis. The trial’s primary objective was to demonstrate the superiority of DW5121 over DW51212 and DW51211 in reducing bronchitis symptoms, as measured by the Bronchitis Severity Score (BSS). DW51212 was given orally for 7 days and assessed against active and placebo comparators in this study. The specific composition, mechanism of action, and pharmacological class of DW51212 are not disclosed in the available sources. The developer and trial sponsor is Daewon Pharmaceutical.